In April 2014, the US company announced the acquisition of Genome Compiler Corporation, an Isreali-based company providing software for genentic engineers, molecular and synthetic biologists, to strengthen its position as the technology leader in DNA synthesis.

It provides synthetic genes used in research and development by many of the leading names in big pharma around the world.